IFW

Date of Deposit: June 4, 2004

2004 S

hereby certify under that this correspondence is designed with the United States Postal vice as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, yexandria, VA 22313-1450, with sufficient postage on the date indicated

Name: 1

Signature:

Docket No. 1010/102US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kati A. Chevaux, et al.

Filed:

March 1, 2004

Group Art Unit:

Serial No:

10/790,289

Examiner:

For: Products Containing Polyphenol(s) and L-Arginine and Methods of Use Thereof

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

Applicants respectfully request the Examiner's consideration of the cited references and entry into the record of this application and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104 and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

The present Information Disclosure Statement has been submitted prior to the receipt of an Office Action in this application. Accordingly, no fee is due. However, in the event that a first Office Action was mailed on or before the date of submission of this disclosure statement, the Commissioner is hereby authorized to charge any fees to deposit Account No. 50-2549.

Date:

June 3, 2004

Respectfully submitted,

Nada Jain

Reg. No. 41,431 &

NADA JAIN, P.C.

560 White Plains Road, Suite 460

Tarrytown, NY 10591 Telephone: (914) 333-0610

Fax: (914) 333-0615

FORM PTO-1449 U.S. cpartment of commerce Patent and Trade
INFORMATION DISCLOSURE STATEMENT mmerce Patent and Trademark Office

(Use several sheets if necessary)

Serial No. 10/790,289

Inventors: Kati A. Chevaux, et al.

Docket No. 1010/102US4

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,362,505	11/94	Hsieh, et al.			
	4,948,600	8/90	Zumbe, et al.			
	4,619,831	10/86	Sharma			
	5,554,645	9/96	Hammerstone, et al.			
	4,797,421	1/89	Koshiyama, et al.			
	5,431,912	7/95	N Guyen			
	5,585,135	12/96	Patterson, et al.			
	6,015,913	1/2000	Kealey, et al.			
	5,820,910	10/98	Jury, et al.			
	5,945,452	9/99	Cooke, et al.			
	6,469,053	10/2002	Romanczyk, et al.			
	4,871,557	10/89	Linscott			
	4,421,771	12/83	Stock, et al.			- t
	4,704,292	11/87	Kattenberg			
	4,797,421	1/89	Ariga, et al.			
	5,484,594	1/96	Frangi, et al.			
	5,217,997	1/93	Levere			
	5,428,070	1/95	Cooke, et al.			
	5,543,430	8/96	Kaesemeyer			
	6,063,432	5/00	Maxwell, et al.			
	4,364,967	12/82	Black			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
	1	97 36497 A	10/97	wo	Yes
	2	2 725 113 A	4/96	FR	Yes – Abstract Only
	3	2 384 461 A	10/78	FR	Yes – Abstract Only
	4	7 213251 A	8/95	JР	Yes - Abstract Only
	5	98 33494 A	8/98	wo	Yes
	6	76074	1/82	RO	Yes
	7	8 205818	8/96	JP	Yes - Abstract Only
	8	98/09533	3/98	wo	Yes

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.			
	9	Klahr, S., The Role of L-Arginine in Hypertension and Nephrotoxicity, Current Opinions in Nephrology and Hypertension, 7:547-550(1998)			
	10	Sabate et al., Effects of Walnuts on Serum Lipid Levels and Blood Pressure in Normal Men, New England Journal of Medicine 1993, 328:603-607			
	11	Sabate et al., Nuts: A New Protective Food Against Coronary Heart Disease, Current Opinion in Lipidology, 1994, 5:11-16			
	12	Rossitch, Jr., L-Arginine Normalizes Endothelial Function in Cerebral Vessels from Hypercholesterolemic Rabbits, J. Clin. Invest., 1991, 87:1295-1299			
	13	Arginine: NO More Than a Simple Amino Acid?, The Lancet, 1997, 350:901-902			
	14	Girerd et al., L-Arginine Augments Endothelium-Dependent Vasodilation in Cholesterol-Fed Rabbits, Circulation Research, 1990, 67:6 1301-1308			
	15	Drexler et al., Correction of Endothelial Dysfunction in Coronary Miscrocirculation of Hypercholesterolaemic Patients by L-Arginine, The Lancet, 1991, 338:1546-1550			
	16	Creager et al., L-Arginine Improves Endothelium-Dependent Vasodilation in Hypercholesterolemic Humans, J. Clin. Invest., 1992, 90:1248-1253			
	17	Cooke et al., Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta, Circulation, 1991, 83:3 1057-1062			
	18	Cooke et al., Anti-Atherogenic Effect of Nuts: Is the Answer NO?, Arch Intern Med, 1993, 153-896-899			
	19	Clarkson, et al., Oral L-Arginine Improves Endothelium-Dependent Dilation in Hypercholesterolemic Young Adults, J. Clin. Invest., April 1996, 97:8, 1989-94			

EXAMINER	DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if no in conformance and not considered. Include copy of this form with next communication to applicant.					